The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...
Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.